Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × amivantamab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Salivary Gland Neoplasms 1 RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Non-small Cell Lung Cancers 1 Lung Neoplasms 1 Locally Recurrent Skin Squamous Cell Carcinoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1

Interventions

pembrolizumab 155 Gemcitabine 146 Paclitaxel 134 Carboplatin 120 Bevacizumab 116 Docetaxel 100 Cyclophosphamide 100 Cisplatin 99 Exercise 82 Nivolumab 81 Capecitabine 80 Fluorouracil 78 Dexamethasone 74 Irinotecan 68 Oxaliplatin 62 Pemetrexed 60 Radiotherapy 59 Leucovorin 57 Standard of Care 56 Cetuximab 50 Blood Specimen Collection 48 Sorafenib 47 Drug Therapy 47 Erlotinib Hydrochloride 46 Doxorubicin 44 atezolizumab 41 130-nm albumin-bound paclitaxel 39 trametinib 37 Ipilimumab 36 Albumin-Bound Paclitaxel 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03767075 2024-04-25

BoB

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡